Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Biodesix Inc-Direktor Jack Schuler kauft Aktien im Wert von 234.000 US-Dollar | 1 | Investing.com Deutsch | ||
Mi | BDSX stock touches 52-week low at $1.15 amid market challenges | 2 | Investing.com | ||
13.11. | Biodesix CFO Robin Harper Cowie verkauft Aktien im Wert von 1.355 US-Dollar | 1 | Investing.com Deutsch | ||
13.11. | Entwicklungsleiter von Biodesix verkauft Aktien für 595 US-Dollar | 1 | Investing.com Deutsch | ||
13.11. | Biodesix-Vertriebsleiter verkauft Aktien im Wert von 644 US-Dollar | 1 | Investing.com Deutsch | ||
BIODESIX Aktie jetzt für 0€ handeln | |||||
13.11. | Biodesix-Chefbuchhalter verkauft Aktien im Wert von 283 US-Dollar | 1 | Investing.com Deutsch | ||
13.11. | Biodesix-CEO Scott Hutton verkauft Aktien im Wert von 5.219 US-Dollar | 1 | Investing.com Deutsch | ||
06.11. | Biodesix-Direktor Matthew Strobeck erwirbt Aktien im Wert von 55.915 US-Dollar | 2 | Investing.com Deutsch | ||
06.11. | Biodesix-Direktor Jack Schuler kauft Aktien im Wert von 136.000 US-Dollar | 2 | Investing.com Deutsch | ||
06.11. | Biodesix-Direktor Massarany erwirbt Stammaktien im Wert von 30.865 US-Dollar | 1 | Investing.com Deutsch | ||
06.11. | Biodesix-Vorstandsvorsitzender John Patience erwirbt Aktien im Wert von 103.710 US-Dollar | 1 | Investing.com Deutsch | ||
06.11. | Biodesix-Direktor Kennedy Lawrence T. Jr. erwirbt Aktien im Wert von 97.068 US-Dollar | 1 | Investing.com Deutsch | ||
04.11. | Biodesix, Inc. (NASDAQ:BDSX) Q3 2024 Earnings Call Transcript | 3 | Insider Monkey | ||
01.11. | Biodesix GAAP EPS of -$0.07 beats by $0.01, revenue of $18.2M misses by $0.32M | 1 | Seeking Alpha | ||
01.11. | Biodesix, Inc.: Biodesix Announces Third Quarter 2024 Results and Highlights | 73 | GlobeNewswire (Europe) | Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast... ► Artikel lesen | |
24.09. | Farallon Capital Management LLC Purchases New Stake in Biodesix, Inc. (NASDAQ:BDSX) | 1 | MarketBeat | ||
15.08. | BIODESIX INC - 8-K, Current Report | - | SEC Filings | ||
13.08. | Biodesix CFO sells over $1,500 in company stock | 1 | Investing.com | ||
13.08. | Biodesix executive sells shares worth $740 amid automatic tax-related sale | 1 | Investing.com | ||
13.08. | Biodesix executive sells over $300 in stock, prices range $1.52 to $1.64 | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PAION | 0,006 | -21,05 % | Unglaubliche Prognose für Montag setzt Paion Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
EPIGENOMICS | 1,000 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
GINKGO BIOWORKS | 6,350 | +0,79 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
RECURSION PHARMACEUTICALS | 5,755 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
GUARDANT HEALTH | 29,010 | -1,86 % | Guardant Health Stock Sees RS Rating Jump To 83 | ||
BEAM THERAPEUTICS | 23,580 | -3,72 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
ONCOLYTICS BIOTECH | 0,935 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
ARCTURUS THERAPEUTICS | 17,070 | +5,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
SIGA TECHNOLOGIES | 6,260 | +0,16 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
ADMA BIOLOGICS | 21,295 | -0,35 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
VIR BIOTECHNOLOGY | 6,955 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
VERVE THERAPEUTICS | 4,600 | +1,10 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
TRAVERE THERAPEUTICS | 17,000 | -2,86 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level |